Introduction
Paclitaxel (Taxol ) is an anticancer drug with a broad spectrum of antitumor activity, including breast, ovarian, skin and lung cancer. 1 It was originally isolated from the Pacific yew tree Taxus Brevifolia, 2 and together with the drug docetaxel represents the antineoplastic taxanes. The taxanes have a unique mechanism of action among chemotherapeutic agents in that the drugs facilitate the formation and suppress the depolymerization of microtubules.
Exposed cells are blocked in the G2/M phase in the cell cycle and eventually undergo apoptosis. 3, 4 Paclitaxel also induces apoptosis directly, but this may be a result of different mechanisms at different drug concentrations. 5 Paclitaxel is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes, CYP3A4 and CYP2C8. CYP3A4 metabolizes paclitaxel to p-3'-hydroxypaclitaxel and CYP2C8 converts the drug to 6 -hydroxypaclitaxel and these metabolites can be further oxidized to 6 -,p-3'-dihydroxypaclitaxel. 6 Other metabolites have been identified in smaller quantities. 7 Studies have shown that the major portion of unchanged paclitaxel and its metabolites are excreted in the feces, indicating extensive nonrenal clearance. 8 However, only paclitaxel has been shown to be toxic and to have an antitumor activity while its metabolites are considered to be inactive. 9 Since the beginning of the 1990s, when Taxol was introduced as an anticancer drug, 10 an extensive number of pharmacokinetic studies have been done on the substance. These studies have resulted in the development of several different methods for quantification of paclitaxel in biological samples. The concentrations of paclitaxel and its metabolites in human plasma are measured preferably by HPLC or LC-MS 11 , although other techniques have also been 2010-05-27
reported. Immunological methods such as enzyme-linked immunoassay (ELISA) 12 and radioimmunoassay 13 have been used for screening human plasma, but these methods have a major drawback of cross reactions. Most frequently used are HPLC systems with UVdetection, although other chromatography techniques, e.g. capillary electrophoresis 14 and methods using other detectors, e.g. fluorescence detectors, 15 have also been reported.
Several developments in the use of paclitaxel have led to lower plasma concentrations of the drug and the need for more sensitive assays. First of all, clinicians have begun to investigate weekly therapy as an alternative to the every-three-week administration schedule, with a reduction of dose as a result. 16 In the development of new chemotherapeutic regimens where paclitaxel is used in combination with other drugs, the dose is often less than the recommended phase II dose. In addition, the investigation of individualization of chemotherapy has also led to the need for more accurate techniques. The relative lack of sensitivity and specificity of the HPLC methods with UV-detection 17 has led to the development of methods using mass spectrometry and multiple MS for detection of the substances. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Recent reports have described paclitaxel quantifications based on LC-MS-MS instrumentation. Several different extraction methods, mobile phases, columns, interfaces and MS instruments have been used. However, most of these methods were developed for paclitaxel only and not for the metabolites. For our purposes of trying to predict cancer patient's individual elimination of paclitaxel by investigating factors affecting the extent of conversion by each metabolic enzyme, we needed an accurate and sensitive method for quantification of paclitaxel and its metabolites in human plasma.
The aim of our study was to develop an LC-MS method for simultaneous quantification of paclitaxel and its metabolites in human plasma. To our knowledge, this is the first method for 2010-05-27
quantification of paclitaxel, 6 -hydroxypaclitaxel, p-3´-hydroxypaclitaxel and p-3'-,6 -dihydroxypaclitaxel in human plasma using an ion trap mass spectrometer with a sonic spray ionization interface. 
Material and Methods

Material
Solid phase extraction
The solid phase extraction (SPE) was adopted from Huizing et al., 1995, 32 with modifications.
Prior to extraction, the tips in the vacuum box were washed in acetonitrile to minimize crossover. The CN-solid phase (100 mg, 1 mL, Isolute, IST U.K.) columns were conditioned with 2 mL methanol and 2 mL 10 mM ammonium acetate buffer, pH 5. 
LC/MS optimization and settings
Several mobile phases were tested to yield a sensitive and stable chromatography and MS In the Ion Trap Mass Spectrometer positive ion polarity was used, the multiplier voltage being set to 400 V and the peak threshold to 10. The Automatic Sensitivity Control (ASC) was turned on and, for each run, three microscans were centroided and averaged. The mass spectrometer was run in MS 2 mode using two alternating methods. The first MS 2 method was used for detection of paclitaxel and dihydroxypaclitaxel (a reference substance was not available for this metabolite so paclitaxel was used as reference). In the ion accumulation step for this method, the low mass cutoff (LMC) was set to 80, the accumulation mass range was set to 750-940 m/z, the accumulation voltage was set to 0.03 V and the sensitivity was 200.
The settings for the isolation step were as follows: isolation mass range 849-859 and 881-891, During both methods the MS spectra were scanned for a mass-to-charge ratio between 500 and 600 m/z. Chromatograms for each substance were extracted from the MS chromatograms using the product ions as indicated in Table 1 . 2010-05-27
Validation procedure
The precision and accuracy of the method were evaluated by analyzing paclitaxel, p-3´-hydroxypaclitaxel and 6 -hydroxypaclitaxel at five different concentrations (QC1-QC5) on three different days. Six quality control samples at each concentration were used to evaluate within-day variation and six were used for between-day variation. To determine the concentration of the analytes in the QC-samples one calibration curve consisting of nine different concentrations (STD1-STD9) were analyzed each day. Calibration was performed using the area of the corresponding peak in the chromatogram and the calibration curve was created using a cubic-fit regression model forced through zero.
The precision of the assay was expressed as a coefficient of variation (CV) at each 
Results and Discussion
Method Development
The major goal in the development of this assay was to quantify low concentrations of both paclitaxel and its hydroxy metabolites in human plasma. Due to the fact that we only had access to small amounts of the metabolites, the method was first developed for paclitaxel and then the settings were adopted to fit the quantification of the available metabolites and thereafter fine-tuned for the best performance.
In interface. The SSI interface was about 4 times more efficient in ionizing paclitaxel than the ESI. We also had the opportunity to test the ionization on a Perkin Elmer SCIEX equipped with both an ESI and an Atmospheric Pressure Chemical Ionization (APCI) interface. In this system, the ESI was more efficient in ionizing paclitaxel than the APCI interface. The SSI interface was then considered the best choice.
The HPLC column was chosen to retain the analytes sufficiently to avoid ion suppression by early eluting substances in the sample extract and separate the analytes since some of them have identical mass-to-charge ratios for some fragments. The monohydroxymetabolites have the same molecular mass but they fragment into ions with a different m/z. However, p-3´-2010-05-27
hydroxypaclitaxel dissociate into fragments with the same m/z as fragments from paclitaxel and 6 -hydroxypaclitaxel dissociates into fragments with the same m/z as dihydroxypaclitaxel ( Figure 1 ). To achieve single-peak mass chromatograms two methods were run in parallel, one for paclitaxel and dihydroxypaclitaxel and one for the monohydroxymetabolites (Table   1 ). By making sure that the HPLC conditions yielded peak separation, interference between the analytes was minimized. Typical retention times were 6.05 min for paclitaxel, 3.65 min for p-3´-hydroxypaclitaxel, 5.0 min for 6 -hydroxypaclitaxel, 3.3 min for dihydroxypaclitaxel, and 6.8 min for docetaxel. After each injection the chromatography was run for 9 min. Figure 2 shows typical chromatograms for paclitaxel and its hydroxylated metabolites generated from the product ions formed in MS 2 (m/z shown in Table 1 ). Docetaxel was used as an internal standard, however, it did not increase the precision or accuracy of the method and was therefore only used to control the SPE and auto sampler.
Paclitaxel adheres strongly to most surfaces; carry-over effects and ghost peaks were major problems during early method development. The problems were traced to the SPE and solved by replacing the nylon tips in the SPE vacuum box with steel needles, which were washed between all extractions.
Each sample was injected twice due to spiking of the chromatograms. We were not able to get rid of the spiking phenomenon by adjusting the MS conditions or cleaning of the MS, although improving the water quality in the mobile phase helped some. The spiking was, however, rather infrequent, and readily identified, and if one of the chromatograms contained interference, the other injection was used. With more advanced software, it would be rather easy just to exclude a single data point caused by spiking instead of having to run the samples twice. 2010-05-27
Due to the wide range of paclitaxel concentrations found in plasma, the calibration curve for paclitaxel was divided into a low (0.5-250 ng/mL) and high-range (250-7500 ng/mL) calibration curve. The calibration curve was also created using a cubic-fit regression model due to nonlinearity at high paclitaxel concentrations. The response is linear from 0.5 ng/mL up to 1000 ng/mL. Proposed causes of non-linearity at the high end of the calibration curve have been the formation of paclitaxel dimers and trimers at the interface 33 as well as charge transfer in the trap at high ion concentrations. Others have solved this nonlinearity by diluting the samples. 33 However, we found that in the range presented in this assay, the use of nonlinear calibration curves worked just as well. The calibration curves for the metabolites were linear over the whole calibration range. Figure 3 shows a calibration curve for paclitaxel obtained during one of the validation runs.
The final method conditions were chosen for several reasons. First of all they allow the quantification of low concentrations (<10 ng/mL) of the analytes in human plasma. Second, they allow the determination of paclitaxel and its metabolites simultaneously. The method presented here has some special features, especially the use of TFA as a Na-adduct suppressor and the SSI interface, both of which improved the performance of the assay.
Precision and Accuracy
The reproducibility of the method was evaluated by analyzing six replicates of five different QC samples on three different days. Extracted standard curves obtained in the range of 0.5 -7500 ng/mL showed excellent curve fitting with a coefficient of correlation greater than 0.99.
The within-day and between-day variations are reported in Table 2 . The method was found to be acceptably precise (CV < 14 %) and accurate (range 83-113%, except for the within-day 2010-05-27
variation of paclitaxel at the lowest concentration). The mean extraction recovery, assessed at the same concentrations as the QC samples, was a bit low_ paclitaxel range 63-74%, p-3´-hydroxypaclitaxel 65-71%, and 6 -hydroxypaclitaxel 72-85%. The quantification of paclitaxel and its hydroxymetabolites was possible within the range of the standard curves.
The lower limit of quantification was set to 0.5 ng/mL for paclitaxel (within-day precision <12%, n=4, and between-day accuracy 103%-122%, n=3) and to 2 ng/mL for the hydroxymetabolites (within day variation <20%, n=4, and between-day accuracy 107%-125%, n=3).
Stability Experiments
The results of the stability tests on the samples are presented in Tables 2 and 3 . Freeze-thaw cycling did not affect the precision or accuracy of the assay. The substances in plasma were also stable at room temperature for at least 48 h and after reconstitution in the mobile phase, the substances were stable for at least 4 days.
General Discussion
Several mass spectrometry methods have been developed for the quantification of paclitaxel in different matrixes. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] C 6 -labeled paclitaxel was used as an internal standard. The calibration ranges in plasma were 0.1 -100 ng/mL for all compounds. We used a SPE instead of LLE to minimize ion suppression (we also had difficulties with the recovery of the metabolites when using LLE) by unwanted compounds, hopefully giving us a more robust method, and isocratic chromatography since the mobile phase was shown to be of such importance for stable ion formation. Our assay also has a rather wide calibration range of 0.5-7500 ng/mL for paclitaxel, 0.5-750 ng/mL for 6 -hydroxypaclitaxel, and 0.5-400 ng/mL for p-3'-hydroxypaclitaxel, which were chosen according to the concentrations found in human 1 The within-day accuracy on the following three days were 80%, 103% and 88%. 2 For each concentration six samples were tested for the within-day variation, for the between-day variation two samples on three different days (n=6) were used for each concentration and the re-injection was done on the within-day variation samples. 2010-05-27 chromatogram and one the hydroxymetabolites (and the internal standard). Note that the peak at 6.1 min in the p-3´-hydroxypaclitaxel chromatogram is from paclitaxel (more than 100-fold intensity in the correct method) and that the peak at 7 min in the 6 -hydroxypaclitaxel chromatogram is from the internal standard, which has a 13 C fragment with the same m/z as the metabolite. 
